rs587779941
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000179.3(MSH6):c.468_471delAAAG(p.Glu158ProfsTer15) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000179.3 frameshift
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD4 genome Cov.: 33
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:2
The c.468_471delAAAG pathogenic mutation, located in coding exon 3 of the MSH6 gene, results from a deletion of 4 nucleotides at positions 468 to 471, causing a translational frameshift with a predicted alternate stop codon (p.E158Pfs*15). This mutation was seen in an individual from a broad study cohort which included individuals with either colorectal cancer, endometrial cancer, other Lynch syndrome cancers, polyps, adenomas, or a family history of Lynch syndrome cancers in multiple generations (Goldberg Y et al. Clin. Genet. 2015 Jun;87:549-53). This alteration was also identified in one individual (1/10030) diagnosed with both endometrial and ovarian cancer from a cohort of consecutive patients referred for evaluation by an NGS hereditary cancer panel (Susswein LR et al. Genet. Med. 2016 Aug;18:823-32). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
This variant deletes 4 nucleotides in exon 3 of the MSH6 gene, creating a frameshift and premature translation stop signal. This variant is expected to result in an absent or non-functional protein product. This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of MSH6 function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Pathogenic. -
Lynch syndrome 5 Pathogenic:1
This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation. -
Lynch syndrome Pathogenic:1
PVS1; PM2_SUP; PP4 -
not provided Pathogenic:1
This deletion of 4 nucleotides in MSH6 is denoted c.468_471delAAAG at the cDNA level and p.Glu158ProfsX15 (E158PfsX15) at the protein level. The normal sequence, with the bases that are deleted in braces, is AATC{AAAG}GAAG. The deletion causes a frameshift which changes a Glutamic Acid to a Proline at codon 158, and creates a premature stop codon at position 15 of the new reading frame. This variant is predicted to cause loss of normal protein function through either protein truncation or nonsense-mediated mRNA decay. MSH6 c.468_471delAAAG has been observed in an individual with Lynch syndrome (Goldberg 2014). We consider this variant to be pathogenic. -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change creates a premature translational stop signal (p.Glu158Profs*15) in the MSH6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH6 are known to be pathogenic (PMID: 18269114, 24362816). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Lynch syndrome (PMID: 25430799). ClinVar contains an entry for this variant (Variation ID: 127598). For these reasons, this variant has been classified as Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at